The Fastest & Easiest Way to Add News to Your Website.

VERAXA Biotech Poised to Benefit as Novartis’ $1.5 Billion ADC Acquisition Highlights Pharma Demand

Novartis’ acquisition of Myricx Bio for up to $1.5 billion underscores surging pharmaceutical interest in next-generation antibody-drug conjugates, positioning VERAXA Biotech, with its proprietary BiTAC platform, as a po... Read the full article →